A drug developed for diabetes could be utilized to treat Alzheimer’s after researchers discovered it “altogether reversed memory loss” in mice through a triple method of action. In the treatment of Alzheimer’s disease using a drug could bring substantial improvements initially created to treat type 2 diabetes. The research recently published in Brain Research.
Lead researcher Professor Christian Holscher of Lancaster University in the UK said the novel treatment “holds the clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease.”
A common cause of Alzheimer’s disease is dementia and as per Alzheimer’s Society in the UK by 2051 the numbers are expected to rise to two million individuals.
Dr. Doug Brown, Director of Research and Development at Alzheimer’s Society, stated: “With no new treatments in almost 15 years, we have to discover better approaches for handling Alzheimer’s. It’s important that we explore if drugs developed to treat other conditions can benefit individuals with Alzheimer’s and other forms of dementia. This way to research could make it much quicker to get promising new medications to the people who require them.”
Despite the fact that the advantages of these ‘triple agonist’ drugs have so far just been found in mice, other studies with existing diabetes medications such as liraglutide have indicated real promise for individuals with Alzheimer’s, so further development of this work is crucial.” This is the first time when that a triple receptor drug has been utilized to protect the brain from degeneration which acts in multiple ways.
It combines GLP-1, GIP, and Glucagon which are all growth factors. Problems with growth factor signaling have been appeared to be impaired in the brains of Alzheimer’s patients. The examination utilized APP/PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer’s.
Those genes have been found in individuals who have a form of Alzheimer’s that can be inherited. Aged transgenic mice in the advanced stages of neurodegeneration were treated. In a maze test, learning and memory formation were greatly improved by the drug which additionally:- improved levels of a mind development factor which protects nerve cell working; reduced the amount of amyloid plaques in the brain linked with Alzheimer’s; reduced both chronic inflammation and oxidative stress; and slowed down the rate of nerve cell loss.
Professor Holscher stated: “in a few examinations these extremely promising results demonstrate the efficacy of these novel multiple receptor drugs that initially were developed to treat type 2 diabetes but have demonstrated consistent neuroprotective impacts.”
“Clinical studies with an older version of this drug type already indicated very promising outcomes in individuals with Alzheimer’s disease or with mood disorders”.
“Here we demonstrate that a novel triple acting drug indicates promise as a potential treatment for Alzheimer’s however further dose-response tests and direct comparisons with other medications must be led to be conducted in order to evaluate if these new medications are better than previous ones.”
For Alzheimer’s, type 2 diabetes is a risk factor and has been implicated in the progression of the disease. Impaired insulin has been linked to cerebral degenerative processes in type 2 diabetes and Alzheimer’s disease. Insulin desensitization has also been seen in the Alzheimer’s disease brain.
As insulin is a growth factor with neuroprotective properties, the desensitization could play a role in the development of neurodegenerative disorders.